Cellectar to Restate Previously Issued Financial Statements - Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq
FLORHAM PARK, N.J., Aug. 23, 2024 ( GLOBE NEWSWIRE ) -- Cellectar Biosciences, Inc. ( NASDAQ: CLRB ) , a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the Company had received ...
| Ticker |
Sentiment |
Impact |
|
META
|
Somewhat Bullish
|
7 %
|
|
CLRB
|
Neutral
|
21 %
|
